Bellerophon Therapeutics Inc
NASDAQ:BLPH
Bellerophon Therapeutics Inc
NASDAQ:BLPH
Price:
0.0625 USD
21.83%
Market Closed
Updated:
May 3, 2024
Bellerophon Therapeutics Inc
Net Income (Common)
|
Bellerophon Therapeutics Inc
Net Income (Common) Peer Comparison
Comparables:
BDX
BSX
SYK
ABT
ISRG
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Bellerophon Therapeutics Inc
NASDAQ:BLPH
|
Net Income (Common)
-$12.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
6%
|
CAGR 10-Years
3%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Income (Common)
$1.8B
|
CAGR 3-Years
106%
|
CAGR 5-Years
0%
|
CAGR 10-Years
17%
|
|
|
Stryker Corp
NYSE:SYK
|
Net Income (Common)
$3.4B
|
CAGR 3-Years
34%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
16%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Income (Common)
$5.6B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
17%
|
CAGR 10-Years
9%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Income (Common)
$2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
12%
|
CAGR 10-Years
14%
|
See Also
What is Bellerophon Therapeutics Inc's Net Income (Common)?
Net Income (Common)
-12.4m
USD
-12.4m
USD
Based on the financial report for Jun 30, 2023, Bellerophon Therapeutics Inc's Net Income (Common) amounts to -12.4m USD.
What is Bellerophon Therapeutics Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
21%
21%
Over the last year, the Net Income (Common) growth was 34%. The average annual Net Income (Common) growth rates for Bellerophon Therapeutics Inc have been 10% over the past three years , 21% over the past five years .
You don't have any saved screeners yet
